Influence on erythropoietin levels of treatment with cisplatinum-endoxan.
Erythropoietin levels have been determined in 24 patients with different gynecologic malignancies, who were treated with cisplatinum and endoxan. A statistically highly significant decrease was demonstrated 2 h after starting treatment with a further significant decrease at 6 h. After 12 h the erythropoietin concentrations returned to values similar to those before treatment started.
Lechner
W
W
Department of Obstetrics and Gynecology, University of Innsbruck, Austria.
Artner-Dworzak
E
E
Sölder
E
E
Sachsenmaier
M
M
Kölle
D
D
Moncayo
H
H
Reitsamer
R
R
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004921:Erythropoietin / Q000097:blood*; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged
D004921:Erythropoietin; D003520:Cyclophosphamide; D002945:Cisplatin